Search
Search Results
-
Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse
IntroductionmSMART classifies high-risk Multiple Myeloma patients into Double Hit and Triple Hit Myeloma (DH/THM) on the basis of the number of...
-
Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3)
BackgroundThe diagnosis of mixed phenotype acute leukemia (MPAL) with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3) is always a...
-
t(1;4) translocation in a child with acute lymphoblastic leukemia: a case report
BackgroundAcute lymphoblastic leukemia is the most common childhood cancer, with an 80% frequency in children between 1 and 10 years old. The outcome...
-
The International Consensus Classification of myelodysplastic syndromes and related entities
The International Consensus Classification (ICC) of myeloid neoplasms and acute leukemia has updated the classification of myelodysplastic syndromes...
-
The study of the impact of additional chromosomal aberrations and c-MYC and BCR::ABL1 genes amplification on CML patient’s characteristics: relation to haematological parameters and patient outcome
BackgroundChronic myeloid leukaemia is characterised by genetic instability which results in additional cytogenetic aberrations that have been linked...
-
Indolent B-cell lymphoma with t(14;19) investigated from a molecular perspective
T(14;19) is an unusual but distinct genomic alteration reported in low-grade B-cell lymphomas. This structural rearrangement places BCL3 in...
-
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome map** uncovers cryptic aberrations of prognostic and therapeutic significance
Chromosome banding analysis (CBA) remains the standard-of-care for structural variant (SV) assessment in MDS. Optical genome map** (OGM) is a...
-
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
BackgroundBCR-ABL1 T315I mutations confer resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Olverembatinib is a new...
-
Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement
Platelet-derived growth factor receptor B ( PDGFRB ) gene rearrangements define a unique subgroup of myeloid and lymphoid neoplasms frequently...
-
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia
Study aimsTo evaluate the outcomes of patients with 3q26.2/MECOM-rearranged chronic myeloid leukemia (CML).
MethodsWe reviewed consecutive adult...
-
Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan
Myeloid and lymphoid neoplasms associated with FGFR1 abnormalities (MLN- FGFR1 abnormalities) are rare hematologic malignancies associated with...
-
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500 mg/day). Efficacy and...
-
Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia
Many studies have confirmed that overexpressed WT1 exists in leukemic cells, especially in AML. However, the immunophenotypic features of this sort...
-
Clinical Outcomes of Pediatric Acute Lymphoblastic Leukemia in the Bajio Region of Mexico: A Retrospective Cohort Study
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood, and the Hispanic race has the highest incidence worldwide . Disparities in...
-
Flow cytometric measurable residual disease in adult acute myeloid leukemia: a preliminary report from Eastern India
Presence of measurable residual disease (MRD) in acute myeloid leukemia (AML) is considered to be an independent predictor of relapse and poorer...
-
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape
Acute myeloid leukemia (AML) accounts for 25% of all leukemia diagnosis and is characterized by distinct cytogenetic and molecular profile. Advances...
-
Analysis of molecular cytogenetic features and PGT-SR for two infertile patients with small supernumerary marker chromosomes
Research questionCan preimplantation genetic testing for structural rearrangement (PGT-SR) with next-generation sequencing (NGS) be used to infertile...
-
Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion
The standard therapies for polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome are radiation therapy,...
-
What is new in acute myeloid leukemia classification?
Recently, the International Consensus Classification (ICC) and the 5 th edition of the World Health Organization classification (WHO2022) introduced...
-
In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes
South Africa (SA) has a high prevalence of human immunodeficiency virus (HIV) infection. People living with HIV are at markedly increased risk of...
